Cargando…
Recent advances in targeted therapy for Ewing sarcoma
Ewing sarcoma is an aggressive, poorly differentiated neoplasm of solid bone that disproportionally afflicts the young. Despite intensive multi-modal therapy and valiant efforts, 70% of patients with relapsed and metastatic Ewing sarcoma will succumb to their disease. The persistent failure to impro...
Autores principales: | Pishas, Kathleen I., Lessnick, Stephen L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007751/ https://www.ncbi.nlm.nih.gov/pubmed/27635231 http://dx.doi.org/10.12688/f1000research.8631.1 |
Ejemplares similares
-
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting
por: Theisen, Emily R., et al.
Publicado: (2016) -
Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation
por: Pishas, Kathleen I., et al.
Publicado: (2018) -
Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma
por: Patel, Priyal O., et al.
Publicado: (2019) -
Network potential identifies therapeutic miRNA cocktails in Ewing sarcoma
por: Weaver, Davis T., et al.
Publicado: (2021) -
Targeting the p53 Pathway in Ewing Sarcoma
por: Neilsen, Paul M., et al.
Publicado: (2011)